In one such trial, 24 patients with relapsed, high-risk melanoma were administered a peptide vaccine composed of melanosomal antigens such as Melan-A/MART-1, MAGE-1, gp100, and tyrosinase, along with granulocyte-macrophage colony-stimulating factor (GM-CSF). The gene discussed is CSF2; the disease is melanoma.